Intelligent Bio Solutions Inc. (Nasdaq: INBS) has announced a new strategic manufacturing partnership with Syrma Johari MedTech Ltd. to support the production of its Intelligent Fingerprinting Drug Screening Reader. This collaboration is expected to result in significant cost savings and margin improvement for INBS, with an anticipated 40% reduction in production costs and a 20% increase in gross margin. Syrma Johari’s manufacturing capacity is four times that of INBS, positioning the company to efficiently meet growing demand and prepare for U.S. market entry in 2026.

The partnership will enhance INBS’ global manufacturing strategy, reduce reliance on a single supplier, and increase resilience in the supply chain. Syrma Johari, with over 45 years of experience in medical device engineering and manufacturing, brings a deep track record in producing regulated medical technology devices. The company’s certification to ISO 13485, MDSAP, FDA, TUV SUD, and GMP standards ensures world-class compliance and quality in medical device manufacturing.

Syrma Johari’s expertise in electronics, mechanical assembly, PCB manufacturing, and clean-room processes positions them to produce INBS’ fingerprint drug-screening reader to a consistently high standard while delivering cost advantages over time. The company’s upcoming medical-grade plastics manufacturing facility in India will further expand its capabilities to meet global demand. Syrma Johari’s regulatory and quality-assurance capabilities align with INBS’ global expansion plans, supporting its regulatory pathways and increasing commercial activity worldwide.

Read more at GlobeNewswire: Intelligent Bio Solutions Announces New Manufacturing